| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 |
|---|---|---|---|---|---|---|---|---|---|
Operating expenses: | |||||||||
Research and development | |||||||||
4,706 | 5,449 | 4,182 | 4,250 | 3,759 | 2,518 | 1,222 | 540 | 663 | 49 |
General and administrative | |||||||||
2,746 | 2,167 | 2,142 | 2,189 | 2,589 | 1,709 | 1,004 | 585 | 374 | 33 |
Total operating expenses | |||||||||
7,452 | 7,616 | 6,324 | 6,439 | 6,348 | 4,227 | 2,226 | 1,125 | 1,037 | 83 |
Loss from operations | |||||||||
-7,452 | -7,616 | -6,324 | -6,439 | -6,348 | -4,227 | -2,226 | -1,125 | -1,037 | -83 |
Other (expense) income, net: | |||||||||
Interest expense | |||||||||
273 | - | 2 | - | - | 229 | 1,221 | 619 | 489 | 15 |
Interest income | |||||||||
220 | 294 | 324 | 375 | 398 | 283 | 27 | 25 | 5 | - |
Other expense, net | |||||||||
-332 | - | -12 | -5 | - | - | - | - | - | - |
Change in fair value of Biocon anti-dilution right | |||||||||
- | - | - | - | - | 818 | 1,497 | 46 | 56 | 42 |
Total other (expense) income, net | |||||||||
-385 | 49 | 310 | 370 | 398 | -764 | -2,691 | -640 | -540 | -57 |
Net loss | |||||||||
-7,837 | -7,567 | -6,014 | -6,069 | -5,950 | -4,991 | -4,917 | -1,765 | -1,577 | -141 |
Other comprehensive income, net: | |||||||||
Unrealized gain on available-for-sale securities, net | |||||||||
138 | -25 | -14 | 39 | 44 | - | - | - | - | - |
Foreign currency translation gain | |||||||||
315 | - | 7 | -1 | - | - | - | - | - | - |
Total other comprehensive income, net | |||||||||
453 | -59 | -7 | 38 | 44 | - | - | - | - | - |
Comprehensive loss | |||||||||
-7,384 | -7,626 | -6,021 | -6,031 | -5,906 | -4,986 | -4,917 | -1,765 | -1,577 | - |
Net loss per share, basic and diluted | |||||||||
-0.45 | -0.43 | -0.35 | -0.35 | -0.34 | -0.34 | -0.44 | -0.16 | -0.15 | -0.01 |
Weighted-average common shares outstanding, basic and diluted | |||||||||
17,562 | 17,383 | 17,376 | 17,376 | 17,376 | 16,258 | 11,078 | 10,715 | 10,708 | 10,708 |